Avadel Pharmaceuticals plcAvadel Pharmaceuticals plcAvadel Pharmaceuticals plc

Avadel Pharmaceuticals plc

No trades
See on Supercharts
Market capitalization
‪1.63 B‬USD
−2.02USD
‪−160.28 M‬USD
‪27.96 M‬USD
Beta (1Y)
1.19

About Avadel Pharmaceuticals plc

CEO
Gregory J. Divis
Headquarters
Dublin
Website
Employees (FY)
154
Founded
2015
ISIN
US05337M1045
FIGI
BBG00FPFX9W4
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.